

If your loved one has PSMA+ mCRPC previously treated with hormone therapy,

CONSIDER

PLUVICTO

A GUIDE FOR
CARE PARTNERS:

Tips for being
an advocate

**AVAILABLE *before*
CHEMOTHERAPY***

*For certain men as determined by their doctor.

Actor portrayal.

What is PLUVICTO[®] (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy and are considered appropriate to delay chemotherapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?


Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

MENU

<u>Your support matters</u>	<u>4</u>
<u>Is he eligible?</u>	<u>6</u>
<u>What is PSMA?</u>	<u>7</u>
<u>What is PLUVICTO?</u>	<u>8</u>
<u>Why PLUVICTO?</u>	
<u>After hormone therapy</u>	<u>9</u>
<u>After hormone therapy and chemotherapy</u>	<u>11</u>
<u>Coverage</u>	<u>14</u>
<u>Novartis Patient Support[™]</u>	<u>15</u>
<u>Important Safety Information</u>	<u>16</u>



*"We got to where we are by
believing in each other
and by turning to each other as a
source of strength."*

—Anne, wife and care partner of a PLUVICTO patient

Please see [Important Safety Information](#) on pages 16-17.

As a care partner YOUR SUPPORT MATTERS

Facing a loved one's metastatic cancer diagnosis is difficult. He needs you now more than ever. Here are some steps to help you advocate for him in this crucial time.



STEP 1: Start the conversation. Ask your loved one and his doctor questions:

- How will we know if PLUVICTO is right for him now?
- Is he PSMA+? Does he need a PSMA-PET scan?
- What are our goals for treatment? Next steps?

PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

IMPORTANT SAFETY INFORMATION (continued)


PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see [Important Safety Information](#) on [pages 16-17](#).

YOUR SUPPORT MATTERS (continued)



STEP 2: Find a path forward on your journey

Some treatments may better fit the treatment goals of your loved one and his doctor. Your advocacy can help in finding the best options for him.



STEP 3: Learn about his treatment options

Start your research at [PLUVICTO.com](https://pluvicto.com).

Your loved one may be able to receive PLUVICTO earlier in his journey. Talk to your care team about all the treatment options, including whether he is eligible to delay chemotherapy and begin PLUVICTO.


IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

Please see [Important Safety Information](#) on [pages 16-17](#).

If your loved one's prostate cancer is progressing, IS IT TIME FOR SOMETHING DIFFERENT?



If his cancer has spread outside the prostate and no longer responds to hormone treatment that lowers testosterone, **PLUVICTO could be right for him.**

Chemotherapy: Treatment that uses chemicals to kill fast-growing cells in the body. This includes cancer cells.

Hormone therapy: Treatment that interferes with the effects of testosterone.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby.

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent infertility.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

If your loved one's PSA level rises,

IS IT TIME TO ASK ABOUT HIS PSMA STATUS?

PSMA is a biomarker that can be found on prostate cancer cells and some normal cells. If your loved one has higher levels of PSMA, he is considered PSMA+.

You can find out his status by having an imaging test called a PSMA-PET scan.

>80%

of men with prostate cancer are PSMA+.
This means your loved one may be too.
Talk to his doctor to discover his status.

Biomarker: Something that can tell the doctor more about your loved one's cancer.

PSMA-PET scan: An imaging test that can find PSMA+ cells, including prostate cancer cells, in the body.

PSA, prostate-specific antigen.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

WHAT IS PLUVICTO?

PLUVICTO is not chemotherapy.

It is the **FIRST** and **ONLY** radioligand therapy (RLT) for PSMA+ mCRPC.

- RLT is a different type of radiation therapy that is injected or infused
- PLUVICTO is an RLT that targets a biomarker called PSMA

PLUVICTO is:

- Given through an intravenous (IV) injection or infusion
- Given every 6 weeks for up to 6 doses

mCRPC, metastatic castration-resistant prostate cancer.



IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

IF HE'S TRIED HORMONE THERAPY

The PSMAfore trial:
Included 468 men with PSMA+
prostate cancer that spread outside
their prostate.

They were divided into 2 groups:

- 234 men were treated with PLUVICTO
 - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 234 men were treated with a second hormone therapy

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious
side effects, including:

Low level of blood cell counts.
Tell your doctor right away
if you develop any new or
worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers



Please see additional [Important Safety Information](#) on [pages 16-17](#).

WHY PLUVICTO?

In the PSMAfore clinical trial, PLUVICTO was shown to provide benefits, including:

2x

More time without cancer worsening

Median radiographic progression-free survival (rPFS) was 9.3 months for men on PLUVICTO compared to 5.6 months on a second hormone therapy.

In an updated analysis 17 months later*:

- Median rPFS was **11.6 months** for men on PLUVICTO and **5.6 months** for men on a second hormone therapy

*Additional analysis conducted to learn more about rPFS in PLUVICTO patients.

Overall survival

Median overall survival (OS) was higher in patients who had PLUVICTO (24.5 months) compared to patients on a second hormone therapy (23.1 months). These results were not statistically significant.

49%
of men

Had tumors shrink or disappear[†]

On PLUVICTO, **49%** of men saw their tumors shrink or disappear compared to **14%** with a second hormone therapy. That's 3.5 times as many.

This data point is called overall response rate (ORR), which is calculated by adding complete response (CR) and partial response (PR), which was:

- CR: **21%** with PLUVICTO vs **2.8%** with a second hormone therapy
- PR: **28%** with PLUVICTO vs **11%** with a second hormone therapy

[†]Measuring ORR was not the main goal of the PSMAfore trial. It was not statistically significant. It does not impact the results for rPFS.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

IF HE'S TRIED HORMONE THERAPY AND CHEMOTHERAPY

The VISION trial:
Included 831 men with PSMA+
prostate cancer that spread outside
their prostate.

They were divided into 2 groups:

- 551 men were treated with PLUVICTO plus standard therapy*
 - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 280 men were treated with standard therapy alone

*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (²²³Ra), or drugs still being studied.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby.

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent infertility.



Please see additional [Important Safety Information](#) on pages 16-17.

WHY PLUVICTO?

In the VISION clinical trial, PLUVICTO was shown to:

15
months

Help patients live longer

Median OS was **15.3 months** for men on PLUVICTO plus standard therapy compared to **11.3 months** on standard therapy alone.

9
months

Give people more time without cancer worsening

Median rPFS was **8.7 months** for men on PLUVICTO plus standard therapy compared to **3.4 months** on standard therapy alone.*

*rPFS results may be misread. In the clinical trial, many patients treated with standard therapy alone dropped out early.

49%
of men

Help tumors shrink or disappear

On PLUVICTO plus standard therapy, **49%** of men saw their tumors shrink or disappear (ORR) compared to **1.6%** with standard therapy alone.

- CR: **9%** with PLUVICTO vs **0%** with standard therapy
- PR: **40%** with PLUVICTO vs **1.6%** with standard therapy

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional [Important Safety Information](#) on [pages 16-17](#).



*"I would not be
where I am today without support.
It's that important."*

—PLUVICTO patient about his wife

Please see [Important Safety Information](#) on pages 16-17.

COVERAGE

When his health care provider has decided it's time for your loved one to start treatment with PLUVICTO, here's what you'll need to know about PLUVICTO coverage.

PLUVICTO may be accessible to most insured men*

More than **80%** of insured men benefited from coverage for PLUVICTO as of January 2025

The other 20% of men do not have available policies and/or situations may be decided on an individual basis. Follow up with your plan to determine your coverage.

More than **8 out of 10** men covered paid \$0 out of pocket per infusion

This is based on a study from 2023 to 2024. Approximately 85% of patients in the study paid \$0 for PLUVICTO. Out-of-pocket costs for PLUVICTO for remaining patients vary. It may be as high as the full price of the product. There may also be added costs related to treatment, including but not limited to administration fees.

*This is not a guarantee of coverage. Patient out-of-pocket costs may vary. Coverage and reimbursement decisions vary.

This coverage data comes from patients who had taken hormone therapy and chemotherapy.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

NOVARTIS PATIENT SUPPORT[™]

Once your loved one and his health care provider decide to begin PLUVICTO, Novartis Patient Support is here to help.

We can help:



Navigate the insurance process



Get financial support*



Find answers to questions across the treatment journey

If he has already been prescribed PLUVICTO, sign up for Novartis Patient Support.



Call 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays. Ask his health care provider to help him sign up for assistance.

Get financial support*

If he has private insurance, he could be eligible for Co-Pay Plus and **pay as little as \$0** for his PLUVICTO treatment.

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare, Medicaid, or any other federal or state program. Offer subject to a maximum benefit per course of treatment. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms and Conditions in the enrollment forms for details.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional [Important Safety Information](#) on [pages 16-17](#).

IMPORTANT SAFETY INFORMATION

What is PLUVICTO[®] (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy and are considered appropriate to delay chemotherapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see full [Prescribing Information here](#).

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call [1-800-FDA-1088](tel:1-800-FDA-1088).

Please see full [Prescribing Information here](#).



In his journey, how could PLUVICTO help?
Ask about PLUVICTO today.

Over 20,000 men have already taken PLUVICTO

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

It could be his
NEXT STEP.
Click or visit
[PLUVICTO.com](https://pluvicto.com)
to discover
how.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2025 Novartis

9/25

FA-11513685



Please see additional Important Safety Information on pages 16-17.